Iterion Therapeutics
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd Ste J608, Houston, Te...Phone Number
(832) 721-5208Website
www.iteriontherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Iterion Therapeutics
Founded in 2014, Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear -catenin, an oncology target implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Iterion is also pursuing development in additional cancers where nuclear -catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma, and other solid tumors. The company is headquartered in Houston, Texas.Explore more
Iterion Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iterion Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Iterion Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Iterion Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Iterion Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Iterion Therapeutics
Funding: Get notified immidiatlly once Iterion Therapeutics has new funding data
Check out if Iterion Therapeutics is spiking on competitors!
Check if Iterion Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Iterion Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Iterion Therapeutics
Compare insights from companies similar to Iterion Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Iterion Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iterion Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iterion Therapeutics.
Iterion Therapeutics financials insights
Gather financial insights about Iterion Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$1M
2020
Debt
$150K
2021
Series B
$17M
Iterion Therapeutics Tech Stack
A closer look at the technologies used by Iterion Therapeutics
Most Recent Scoops
Left Company
Executive Move
Ruolan Han, Director, Translational Research, has left the organization and now serves as the Vice President of Nonclinical and Translational Medicine at OncoNano Medicine.
New Hire
Executive Move
Funding
Funding
Iterion Therapeutics News & Media
Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
Two additional investigator-sponsored trial posters featuring tegavivint clinical studies in EGFR-mutated NSCLC and pediatric osteosarcoma will also be presented HOUSTON, May 4, 2026 /PRNewswire/ -- Iterion Therapeutics, a clinical-stage biopharmaceutical company developing novel...Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting
Novel TBL1 targeting strategy drives nuclear β-catenin degradation, inhibits oncogenic transcription, and demonstrates potent anti-tumor activity in complex solid tumors The company continues to build clinical momentum in hepatocellular carcinoma while expanding development into...Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed
Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026...Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma HOUSTON, Feb. 10, 2026 /PRNewswire/ --...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iterion Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2014, Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear -catenin, an oncology target implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Iterion is... Read More
